I
IGC Pharma, Inc. (IGC)
0.26
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.26
0.00 (0.00%)
IGC Pharma, Inc., klinik tadqiqot bosqichidagi farmatsevtika kompaniyasi, neyropsixiatrik va neyrodegenerativ kasalliklar uchun yangi terapevtik nomzodlarni ishlab chiqadi, AQSh va Kolumbiyada Altsgeymer kasalligiga asosiy e'tibor qaratadi. Kompaniyaning asosiy mahsuloti IGC-AD1 bo'lib, u Altsgeymer kasalligidan kelib chiqqan demensiya uchun qo'zg'alishni davolash bo'yicha II fazali klinik sinovda. Uning preklinik bosqichidagi mahsulot nomzodlari orasida Altsgeymer kasalligini davolash uchun TGR-63 va IGC-M3 mavjud. Bundan tashqari, kompaniya sog'liqni saqlash provayderlari uchun sun'iy intellektga asoslangan yordamchi dastur MINT-ADni ishlab chiqmoqda. Kompaniya ilgari India Globalization Capital, Inc. nomi bilan tanilgan va 2023 yil mart oyida IGC Pharma, Inc. nomini o'zgartirgan. IGC Pharma, Inc. 2005 yilda tashkil etilgan va Merilend shtatining Potomac shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Mr. Ram Mukunda | Founder, President, CEO & Director |
| Mr. Rohit Goel CPA, M.B.A. | Director of Accounting & Senior Director |
| Susana Salgar | Sales Manager |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-18 | 10-KT | igc10kt123125.htm |
| 2026-03-12 | 8-K | igc8k031126.htm |
| 2026-01-02 | 8-K | igc8k010226.htm |
| 2025-12-15 | 8-K | igc8k121525.htm |
| 2025-12-03 | S-3/A | igcs3a112325.htm |
| 2025-11-17 | S-3 | igcs3111425.htm |
| 2025-11-14 | S-8 | igcs8103125.htm |
| 2025-10-14 | 8-K | igc8k101025.htm |
| 2025-10-01 | 8-K | igc8k100125.htm |
| 2025-08-19 | DEFA14A | igcdefa14a081825.htm |